BioConnection, Contract Development and Manufacturing Organization, proudly announces that is has won the FD Gazellen status. This prestigious award is given by the Financieel Dagblad to financially healthy companies that have reached yearly revenue growth of more than 20% in the last 3 years.
Dr. Alexander Willemse, CEO of BioConnection: “We’re very excited to win one of the Gazelle awards. We have grown fast and steady in recent years. The highlight came early this year when we acquired the Aletta Jacobs building from MSD enabling us to
have our own manufacturing facility and expand our capabilities and capacity. It is also a reward for all the employees of BioConnection and their dedicated work and to our customers for their trust in us. We definitely look with confidence to the future.
About BioConnection B.V.
BioConnection B.V. (www.BioConnection.eu) is a Dutch contract development and manufacturing organization for the development and production of injectable (bio)pharmaceutical products. BioConnection specializes in: Drug Product development (formulation, analytics, lyophilisation), fill & finish and lyophilisation at clinical and commercial scale. BioConnection offers services based on tailor made solutions and customer-focused flexibility from its own plant and through our trusted partners.
About the FD Gazellen Award
To qualify for an FD Gazelle Award a company must have achieved net sales growth of at least 20 percent per year over the last 3 years. It is also important that the organization has a stable and healthy financial position. The most recent financial year should be concluded with a positive result and their may only be one year of financial loss in the previous period.